https://doi.org/10.4081/aiua.2025.13318
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

A comprehensive systematic review of studies on the potential of A49T and V89L polymorphism in SRD5AR2 as high susceptibility gene association with benign prostate hyperplasia and prostate cancer

Authors

Revina Maharani
https://orcid.org/0009-0007-4123-980X
Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Hotma Lestari
https://orcid.org/0000-0002-9234-4382
Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Putra Mahakarya Dewa
https://orcid.org/0009-0009-0542-5941
Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Dewangga Yudisthira
https://orcid.org/0000-0002-3317-1602
Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Nasim Amar
Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Besut Daryanto
urobes.fk@ub.ac.id
https://orcid.org/0000-0002-0776-1633
Urology Department, Faculty of Medicine Universitas Brawijaya; Dr. Saiful Anwar General Hospital, Malang, Indonesia.

Introduction and objectives: Being the most common disease in aged men, the etiology of benign prostatic hyperplasia (BPH) is not fully defined. Recent studies have reported that the association between BPH and metabolic genes is still inconsistent. A gene connected with BPH is SRD5AR2, whose polymorphisms, A49T and V89L, have distinct enzyme activity. This systematic review examines SRD5AR2 polymorphisms within two alleles (A49T and V89L), assessing their roles as prognostic indicators of malignancy, and response to medication.
Materials and methods: We conducted a search on six different databases, including PubMed, Scopus, Wiley, ProQuest, Cochrane Central, and Science Direct using as string of keywords (BPH) AND [(rs523349) OR (V89L)] AND [(rs9282858) OR (A49T)]. We finally selected seven articles to be extracted. Quality appraisal of clinical trials was evaluated using the Joanna Briggs Institute Approach for systematic reviews.
Results: We sorted nine clinical studies from various countries examining SRDA52 polymorphism and its association of BPH and prostate cancer. About V89L we found that the "LL" genotype, indicating reduced 5α-reductase activity, is linked to a lower BPH risk, while the "VV" genotype may slightly increase BPH risk. About A49T, compared to “AA” genotype, “AT” tends to be associated to higher risk in developing prostate cancer. A49T polymorphism does not show any effect on medical treatment while V89L showed a protective effect on the clinical progression of BPH when treated with 5a-reductase inhibitors, aadrenergic receptor antagonists, and alpha blockers.
Conclusions: SRD5A2 polymorphisms could be a good indicator for prognostic malignancy and a potential tool for personalized medicine of BPH. The findings strongly support the recommendation for further study about SRD5AR2 to enhance its use for screening and prevention and to optimize the medical treatment of BPH.

Dimensions

Altmetric

PlumX Metrics

Plum Print visual indicator of research metrics
  • Mentions
    • News Mentions: 1
see details

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005; 7(Suppl 9):S3-S14.
Goodarzi D, Cyrus A, Khoddami Vishteh HR, et al. Effect of celecoxib on benign prostatic hyperplasia: Results of a preliminary study. Urol Scie. 2011; 22:147-150. DOI: https://doi.org/10.1016/j.urols.2011.07.001
Middleton LW, Shen Z, Varma S, et al. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in
disease pathogenesis. JCI Insight. 2019; 5:e129749.
Li Q, Zhu Y, He J, et al. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis. Molecular biology reports 2013; 40:3597-3608. DOI: https://doi.org/10.1007/s11033-012-2434-x
Choubey VK, Sankhwar SN, Carlus SJ, et al. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not
prostate cancer. Asian Pac J Cancer Prev. 2015; 16:1033-1036. DOI: https://doi.org/10.7314/APJCP.2015.16.3.1033
Salam MT, Ursin G, Skinner EC, et al. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005; 23:246-253. DOI: https://doi.org/10.1016/j.urolonc.2004.12.014
Zeng XT, Su XJ, Li S, et al. Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis. Front Physiol. 2017; 8:688. DOI: https://doi.org/10.3389/fphys.2017.00688
Price DK, Chau CH, Till C, et al. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer. 2016; 122:2332-2340. DOI: https://doi.org/10.1002/cncr.30071
Elzanaty S, Giwercman YL, Giwercman A. Significant impact of 5alpha-reductase type 2 polymorphisms on sperm concentration and motility. Int J Androl. 2006; 29:414-20. DOI: https://doi.org/10.1111/j.1365-2605.2005.00625.x
Neslund-Dudas C, Bock CH, Monaghan K, et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 2007; 67:1654-1663. DOI: https://doi.org/10.1002/pros.20625
Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev. 2001; 10:185-9.
Van Gils CH, Onland-Moret NC, Roest M, et al. The V89L Polymorphism in the 5-α-Reductase Type 2 Gene and Risk of Breast
Cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12:1194-9.
Wang C, Tao W, Chen Q, et al. SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis. Prostate. 2010; 70:170-8. DOI: https://doi.org/10.1002/pros.21050
Li J, Coates RJ, Gwinn M, Khoury MJ. Steroid 5-α-reductase type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: A HuGE review. Am J Epidemiol. 2010; 171:1-13. DOI: https://doi.org/10.1093/aje/kwp318
Giwercman YL, Abrahamsson PA, Giwercman A, et al. The 5alpha-reductase type II A49T and V89L high-activity allelic variants
are more common in men with prostate cancer compared with the general population. Eur Urol. 2005; 48:679-85. DOI: https://doi.org/10.1016/j.eururo.2005.06.011
Tekin Neijmann S, Kural A, Tinay I, et al. Association of missense substitution of A49T and V89L in the SRD5A2 gene with
prostate cancer in Turkish patients. Turk. J. Biochem. 2017; 42:37-43. DOI: https://doi.org/10.1515/tjb-2016-0164
Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia (BPH). BJU Int. 2008; 5:536-44. DOI: https://doi.org/10.1111/j.1464-410X.2008.07667.x
Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 1999; 20:1727-31. DOI: https://doi.org/10.1093/carcin/20.9.1727
Daryanto B, Naim HY, Budaya TN. The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus. Med. Arch. 2023;77:13. DOI: https://doi.org/10.5455/medarh.2023.77.13-17

How to Cite

Maharani, R., Lestari, H., Dewa, P. M., Yudisthira, D., Amar, N., & Daryanto, B. (2025). A comprehensive systematic review of studies on the potential of A49T and V89L polymorphism in SRD5AR2 as high susceptibility gene association with benign prostate hyperplasia and prostate cancer. Archivio Italiano Di Urologia E Andrologia, 97(1). https://doi.org/10.4081/aiua.2025.13318
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.